test

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-Radiotherapy in Primary Unresected Patients with Stage III, IVa, or IVb Loco-Regionally Advanced Head and Neck Squamous Cell Carcinoma

Conditions

Brain and Nervous System | Other Respiratory and Intrathoracic Organs

What is the purpose of this trial?

The purpose of this study is to evaluate the efficacy and safety of Afatinib in maintenance therapy after post-operative radiochemotherapy (66 Gy and Cisplatin at the dose of 100mg/m2 every 3 weeks)in squamous cell carcinoma of the head and neck.


Participation Guidelines

Age:
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Boehringer Ingelheim Pharmaceuticals, Inc.
Dates:
02/10/2014
Last Updated:
Study HIC#:
1208010720